Proteins and Peptides

18 June 2014

Results of a New Study of Brintellix® (vortioxetine) vs. Escitalopram on Sexual Functioning in Well Treated MDD Patients Experiencing Treatment-Emergent Sexual Dysfunction

16 June 2014

Phase 3a Data Showed Liraglutide 3 mg Demonstrated Significantly Greater Weight Loss Compared to Placebo in Adults With Obesity and Type 2 Diabetes

16 June 2014

Halozyme Announces Presentation Of Clinical Data At The American Diabetes Association 74th Scientific Sessions

16 June 2014

New One-year Data of IDegLira Shows Glucose-lowering Effect was Maintained for People with Type 2 Diabetes

16 June 2014

New Phase 3 Study Shows Efficacy and Safety of Victoza® (Liraglutide [rDNA origin] Injection) for the Treatment of Type 2 Diabetes in Adults with Moderate Renal Impairment

16 June 2014

Lilly’s Basal Insulin Peglispro Shows Novel Mechanism of Action

16 June 2014

Studies Show Investigational New Insulin Glargine Product from Lilly and Boehringer Ingelheim Similar Safety and Efficacy Profile to Lantus

16 June 2014

Sanofi’s Lyxumia® (lixisenatide) Showed More Pronounced After-Test-Meal Blood Sugar Lowering than Liraglutide when Both were Added to Insulin Glargine

16 June 2014

Sanofi Reports Positive Phase 3 Results for Toujeo® (insulin glargine [rDNA origin] injection, 300 U/mL)

16 June 2014

Intarcia Presents Interim Phase 3 Data at ADA Showing ITCA 650, A Once Yearly GLP-1, Markedly Reduces Blood Sugar in Patients With Very Poorly Controlled Diabetes

14 June 2014

Affymax and Takeda Announce Termination of Omontys® (peginesatide) Product Collaboration and License Agreement

14 June 2014

GSK presents new data for once-weekly Tanzeum/Eperzan (albiglutide) showing blood glucose lowering up to three years in type 2 diabetes

12 June 2014

Capstone Therapeutics Announces Initiation of Dosing for AEM-28 Phase 1b/2a Human Clinical Trial in Refractory Hypercholesterolemic Subjects

11 June 2014

Xenetic Biosciences Announces Dosing of First Patient on Dialysis in Phase 2a Clinical Study of ErepoXen(R)

11 June 2014

Portola Pharmaceuticals Announces Positive Phase 2 Data With FDA-Designated Breakthrough Therapy Andexanet Alfa and Enoxaparin

7 June 2014

FDA Approves Biogen Idec’s ELOCTATE™, First Hemophilia A Therapy to Extend the Interval between Prophylactic Infusions, for Both Adults and Children

6 June 2014

Xeris Pharmaceuticals, Inc. Announces Dosing of First Patient in Phase 2 Clinical Trial of its Investigational Soluble Glucagon for the Treatment of Mild-to-Moderate Hypoglycemia

5 June 2014

ORBACTIVTM (Oritavancin) Phase 3 Trial Results Published in New England Journal of Medicine

5 June 2014

Halozyme To Resume PEGPH20 Clinical Program In Pancreatic Cancer

3 June 2014

Thrasos Presents Preclinical Data Demonstrating THR-184 Prevents Loss of Kidney Function Following Acute Ischemic Injury

2 June 2014

Neumedicines Publishes Data Demonstrating that HemaMax(TM) (rHuIL-12), but not G-CSF, Significantly Improves Survival After Exposure to Lethal Radiation

2 June 2014

Phase 3 Data Highlight Benefits of Using VELCADE® within Frontline Treatment of Mantle Cell Lymphoma, with Results Showing Significantly Longer Progression-Free Survival Compared to Standard of Care

2 June 2014

VELCADE® (bortezomib)-based Therapy Significantly Improved Progression-Free Survival Compared to Standard Therapy as Frontline Treatment of Patients with Mantle Cell Lymphoma in Phase 3 Study

2 June 2014

Cerenis Reports Two Positive Phase II Studies for HDL Mimetic CER-001 at EAS

2 June 2014

Nektar Presents Positive Preclinical Data for NKTR-214, a Novel Cancer Immunotherapy, at 50th ASCO Meeting

1 June 2014

PROCLAIM(SM) National Patient Registry Analysis Shows Improved Median Overall Survival in Patients with Metastatic Melanoma Treated with High-Dose Interleukin-2 (HD IL-2)

30 May 2014

Angiochem Initiates Phase 2 Clinical Study for Lead Drug Candidate, ANG1005, in HER2+ Breast Cancer with Brain Metastases

29 May 2014

Tarsa Therapeutics Raises $7 Million To Prepare For Filing NDA For Ostora, Its Oral Calcitonin For The Treatment Of Postmenopausal Osteoporosis

28 May 2014

Spectrum Pharmaceuticals Completes Enrollment in Phase 2 Trial of SPI-2012 – A Novel Long-Acting Granulocyte Colony Stimulating Factor (GCSF) to Treat Chemotherapy-induced Neutropenia

27 May 2014

BioMarin Doses First Patient in Phase 3 INSPIRE Trial With BMN 701 for the Treatment of Pompe Disease

News Channels

Newsletter

La Merie Biologics

La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.

Newsletter La Merie Biologics

Newsletter

New Product Alert

La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.

Newsletter new product alert

Featured reports

PD-L1 x 4-1BB (CD137) Bispecific Antibody Pipeline Review

B7-H3-Targeted Immunotherapy Candidates Pipeline Review

CD40 Agonists & CD40/L Antagonists Pipeline Review

Claudin 6: A target opportunity to develop effector-enhanced drug modalities

TCR Engineered T-Cell Therapy 2018: an industry analysis of technologies, pipelines, stakeholders & deals

Biologics Sales Database for Antibodies, Proteins, Biosimilars, Gene & Cell Therapy and RNA

Nectin-4-Targeted Immunotherapy Pipeline Review

RNA-Targeted Small Molecules 2019: a landscape analysis of companies, technologies, targets, investors and partners from an industry perspective

B7-H4 Targeted Antibody Therapy Pipeline Review

5T4-Targeted Immunotherapy Candidates Pipeline Review